查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840896

被忽視的熱帶疾病治療市場：依適應症、藥物類型、通路、最終用戶、給藥途徑和治療方法分類－全球預測，2025-2032年

Neglected Tropical Disease Treatment Market by Disease Indication, Drug Type, Distribution Channel, End User, Route Of Administration, Treatment Approach - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，被忽視的熱帶疾病治療市場將成長至 107.9 億美元，複合年成長率為 6.73%。

關鍵市場統計數據
基準年 2024 64億美元
預計年份：2025年 68.3億美元
預測年份 2032 107.9億美元
複合年成長率 (%) 6.73%

被忽視的熱帶疾病治療優先事項、治療實施挑戰以及實現永續成果的綜合公共衛生干預措施的必要性策略框架

被忽視的熱帶疾病是許多中低收入國家面臨的重大公共衛生挑戰，需要協調一致的臨床、後勤和政策應對措施。近年來，環境變化、人口遷移和衛生系統能力的提升共同導致了治療性介入的優先事項和實施方式轉變。因此，包括公共衛生機構、非政府組織、臨床醫護人員和製藥企業在內的相關人員必須調整其策略，以維持治療效果、擴大治療覆蓋範圍並維護社區信任。

本分析將核心臨床介入置於更廣泛的醫療服務和監管背景下，介紹了當前的治療格局。它強調了整合推廣的必要性，這些策略將大規模藥物整合策略方法與標靶治療相結合，並認知到基層醫療機構、社區健康網路和移動外展服務在彌合醫療服務獲取差距方面發揮的作用。為此，本導言為後續章節奠定了基礎，這些章節將探討制度變革、政策阻力、針對特定細分領域的見解，並為致力於將循證實踐轉化為實際影響的領導者提供切實可行的建議。

科學進步、流行病學變化和採購模式演變如何重新定義被忽視的熱帶疾病治療模式和供應鏈韌性

由於科學創新、人口壓力和政策環境的變化，被忽視的熱帶疾病治療模式正在發生顯著變化。診斷靈敏度和就地檢驗的進步正在縮小臨床發現與及時治療之間的差距，從而支持在傳統大規模藥物管理宣傳活動之外，更精準地使用標靶治療。同時，藥物開發平臺也不斷多元化，包括最佳化的驅蟲方案、聯合治療以及可在資源匱乏地區使用的、劑量方案簡化的抗生素再利用方案。

同時，更廣泛的系統動態正在重塑專案設計。都市化和氣候變遷正在改變病媒生物的棲息地和疾病傳播模式，促使干預區域和季節性計畫進行調整。公共採購和供應鏈韌性正成為關注焦點，相關人員正投資於緩衝庫存、分散式倉庫和數位化庫存系統，以減少配送延誤。最後，公共衛生機構、非政府組織和私人製造商之間的夥伴關係正在不斷擴大，從而催生了聯合資金籌措模式和集中採購機制，提高了採購效率和營運擴充性。

2025 年美國關稅調整重塑了各個治療類別的供應鏈、籌資策略和庫存計劃，從而對營運和採購產生了累積影響。

2025年關稅和貿易政策的調整對被忽視的熱帶病防治項目所用基本藥物的採購動態和供應鏈結構產生了重大影響。原料藥和製劑組分關稅的增加推高了某些藥物類別的到岸成本，促使採購負責人重新評估供應商組合，並在可能的情況下優先考慮本地生產。這促使供應鏈管理人員加快尋找替代供應商、實現物流路線多元化並加強區域合約的步伐，以應對未來的政策變化。

除了直接的成本影響外，關稅帶來的干擾也影響了專案進度和庫存計劃。依賴多層國際供應鏈的組織由於交貨週期延長和合規要求提高，不得不加快訂購速度，並加強海關、監管機構和分銷合作夥伴之間的協調。此外，前置作業時間的影響加劇了現有活性成分和最終產品法規的複雜性，凸顯了統一文件和與國家主管機關積極協調的必要性。因此，專案團隊擴大將貿易政策情境規劃納入年度採購週期，並考慮採用能夠更清晰地在買賣雙方之間分配風險的合約條款。

需要採用以細分市場主導的臨床和採購方法，透過協調適應症需求、治療層級、通路和給藥方式來最佳化專案支付。

要深入了解市場，需要根據適應症、產品類別、給藥管道、最終用戶環境、給藥途徑和治療方法進行細分，這些因素都會影響臨床決策和營運設計。以登革熱、淋巴絲蟲病、盤尾絲蟲病、血吸蟲病和沙眼等疾病為例，各項目的優先事項差異顯著。登革熱的因應措施著重於病媒控制和快速臨床治療，而淋巴絲蟲病和盤尾絲蟲病的應對措施則著重於大規模藥物管理和發病率控制。沙眼防治計畫也將抗生素分發與臉部衛生和環境措施結合。

產品層面的細分同樣影響採購和臨床路徑。驅蟲藥，包括廣泛使用的阿苯達唑、伊維菌素和甲苯達唑等，仍是蠕蟲病控制的基石，需要配製成適合大規模給藥的製劑。抗節肢動物藥和殺蟲劑是病媒控制策略的基礎，通常與藥品一起採購，以提供綜合干預方案。抗生素，例如阿奇黴素和多西環素，在沙眼和某些細菌感染後遺症中發揮不同的作用，影響給藥方案和安全性監測。抗原生動物藥，例如葡甲胺、噴他脒和舒拉明，則針對更專業的適應症，通常需要計畫支持以進行腸外給藥和不利事件監測。

通路也影響藥物取得的動態：政府專案和非政府組織的分銷平台是大規模宣傳活動的主要管道，醫院藥房是複雜病例的轉診點，零售藥房則為日常護理和後續治療提供本地途徑。相應地，最終用戶涵蓋了從提供第一線預防措施的診所和社區健康中心到管理重症或病情迅速進展病例的醫院和流動醫療站。給藥途徑——口服、注射和外用——與服務提供能力相互作用，口服藥物通常優先用於擴大覆蓋範圍，注射藥物用於重症病例，外用藥物則用於輔助治療。

另一方面，標靶治療使臨床醫生能夠根據診斷結果和個別風險狀況來制定個人化治療方案。結合這些細分視角，可以提供多方面的觀點，從而有助於針對不同活動環境進行有針對性的採購、最佳化臨床路徑和客製化監測框架。

美洲、歐洲、中東和非洲以及亞太地區的區域運作實際情況和流行病學差異將決定適應性治療策略和供應選擇。

區域背景對美洲、中東和非洲以及亞太地區的計畫優先事項、監管策略和夥伴關係模式有顯著影響，因為每個地區的流行病學模式和運作限制各不相同。在美洲，都市化趨勢和衛生系統能力的不平衡導致其工作重點既包括應對蟲媒病毒疫情，也包括永續的社區蠕蟲感染疾病控制。該地區的計畫實施者強調與基層醫療衛生基礎設施的整合，並經常利用市政衛生網路來擴大推廣。

在歐洲、中東和非洲，各項專案因應措施面臨不同的法規環境和參差不齊的物流基礎建設。將大規模藥物管理（MDA）宣傳活動與宣傳活動和跨境協調在部分地區尤其重要，因為在這些地區，流離失所和衝突會改變病毒傳播動態，並使供應連續性變得複雜。在亞太地區，郊區人口密度高，加上氣候變遷對病媒生態的影響，促使人們採取季節性干預措施和以學校為基礎的分發模式。此外，當地生產能力的提高和區域採購聯盟的建立，使得供應方案更具韌性，而數位健康工具則為社區層面的監測和依從性監測提供了支持。這些區域差異凸顯了根據當地實際情況調整臨床通訊協定、分發機制和夥伴關係策略的重要性。

製造商、供應商和服務供應商如何透過配方創新、在地化生產和增強分銷能力來重新定義競爭優勢

產業相關人員和公共部門合作夥伴正在適應新的產業格局，在這個格局中，臨床療效、監管狀態和物流能力決定著競爭地位。專注於驅蟲藥和抗生素的製藥商正在投資研發便捷的給藥方法和兒童適用片劑，以方便高劑量給藥並提高患者的用藥依從性。同時，滅蟲劑和殺蟲劑供應商則優先考慮安全性和環境保護，並使其配方與全面的病媒控制方案相契合。隨著相關人員尋求減少對龐大國際供應鏈的依賴，並更靈活地應對本地需求波動，契約製造和本地生產設施的重要性日益凸顯。

服務供應商，包括物流公司和非政府組織執行機構，憑藉其專業知識脫穎而出，例如腸外療法的低溫運輸管理、行動推廣能力以及可即時監測宣傳活動績效的數位追蹤系統。監管諮詢機構和品質保證合作夥伴在加快產品註冊和確保符合國家及地方標準方面發揮著至關重要的作用。這些相關人員共同建構了一個生態系統，因此，在充滿挑戰的營運環境中，協作、透明的合約簽訂以及對能力建設的投資對於保持專案勢頭和擴大服務覆蓋範圍至關重要。

領導者可採取切實可行的策略性舉措，以增強專案韌性、加速服務普及，並使採購和臨床策略與當地營運實際情況相符。

產業領導者和公共衛生管理者可以透過將策略投資與營運實際情況和臨床優先事項結合來提高效率。首先，應優先考慮能夠簡化給藥方式並提高社區接受度的配方和給藥方式創新。其次，應加強區域供應商網路並投資於本地製造夥伴關係關係，以降低貿易政策風險並縮短前置作業時間。

第三，將診斷和監測數據納入採購和宣傳活動規劃，以便在臨床適宜的情況下，將標靶治療與大規模給藥結合。第四，透過採用數位化庫存和追蹤解決方案，提高供應鏈透明度，從而實現庫存的主動重新分配和瓶頸的準確預測。最後，深化跨部門合作，將公共機構、非政府執行機構、臨床服務提供者和私人生產者聚集在一起，協調資金籌措、培訓和社區參與。這些措施共同為領導者提供了一條切實可行的藍圖，以提高計畫韌性並加快應對被忽視的熱帶疾病的進展。

一種透明的方法論，整合了臨床文獻、實施評估、監管分析和相關人員訪談，以真實世界證據為基礎得出操作性結論。

本文的研究結果綜合了來自同儕審查的臨床文獻、專案實施報告、監管公告以及與採購負責人、臨床醫生和供應鏈專家相關人員的訪談等多方面證據。數據綜合優先考慮了近期關於治療有效性和安全性的同行評審研究、大規模藥物管理宣傳活動實施情況的評估以及貿易和採購政策的記錄變化。來自第一線實施人員和生產合作夥伴的定性意見為營運可行性和供應鏈動態評估提供了依據，為技術研究結果提供了實際背景。

此分析方法結合了定性資料的主題綜合分析和不同司法管轄區監管及採購慣例的比較研究。在適用情況下，採用臨床證據與營運經驗相結合的三角驗證方法，以得出關於干預措施適用性和分發策略的結論。調查方法強調資訊來源選擇的透明度、對證據品質的嚴格評估以及反覆的同行檢驗，以確保解釋基於當前的實踐和監管限制。

概述了為持續推進被忽視的熱帶病防治工作而製定的策略重點，強調整合、本地能力建構和數據主導的專案設計。

總之，被忽視的熱帶疾病治療領域正處於曲折點，臨床進展、供應鏈現代化和適應性政策應對必須協同作用，才能維持進展。有效的計畫應將大規模藥物管理與有針對性的臨床干預相結合，並輔以增強的本地生產能力、改進的診斷方法以及能夠提高供應鏈應對力的數位化工具。此外，注重製劑創新和以社區為中心的用藥管理對於擴大覆蓋範圍、同時確保安全性和可接受性至關重要。

展望未來，相關人員應優先考慮跨部門合作、投資本地能力建構以及將監控資料納入專案設計。這樣做將使計畫實施者和生產者能夠更好地預測可能出現的干擾因素，最佳化資源利用，並以公平和永續的方式提供治療。這些共同努力對於在未來幾年保持對抗被忽視的熱帶疾病的勢頭至關重要。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大公私合營，加速被忽視的熱帶疾病藥物研發
  • 將基於智慧型手機的快速診斷測試整合到血吸蟲病社區控制項目中
  • 採用mRNA疫苗平台，為地方性流行區內臟利什曼原蟲症提供一種新型免疫策略。
  • 實施數位化供應鏈管理解決方案，以最佳化被忽視的熱帶疾病治療藥物的「最後一公里」配送。
  • 慈善捐款和影響力投資資金激增，用於治療皮膚利什曼原蟲症的聯合治療
  • 加速監管核准新型大環內酯製劑，以應對盤尾絲蟲病抗藥性挑戰
  • 引入人工智慧驅動的預測模型，以增強被忽視的熱帶疾病藥物研發流程中的標靶識別。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 被忽視的熱帶疾病治療市場（依適應症分類）

  • 登革熱
  • 淋巴絲蟲病
  • 盤尾絲蟲病
  • 血吸蟲病
  • 沙眼

9. 被忽視的熱帶疾病治療市場（依藥物類型分類）

  • 驅蟲藥
    • 阿苯達唑
    • 伊維菌素
    • 甲苯咪唑
  • 抗節肢動物藥物
  • 抗生素
    • 阿奇黴素
    • 多西環素
  • 抗原生動物
    • 葡甲胺
    • 噴他脒
    • 猛擊
  • 殺蟲劑

第10章 被忽視的熱帶疾病治療市場（依通路分類）

  • 政府項目
  • 醫院藥房
  • 非政府組織分發
  • 零售藥房

第11章 被忽視的熱帶疾病治療市場（以最終用戶分類）

  • 診所
  • 社區健康中心
  • 醫院
  • 移動營地

12. 被忽視的熱帶疾病治療市場（依給藥途徑分類）

  • 口服
  • 腸外
  • 外用

13. 被忽視的熱帶疾病治療市場（依治療方法分類）

  • 大規模藥物管理
  • 標靶治療

第14章 各地區被忽視的熱帶疾病治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 被忽視的熱帶疾病治療市場（以群體分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國被忽視的熱帶疾病治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Merck KGaA
    • Pfizer Inc.
    • Sanofi SA
    • Johnson & Johnson
    • Novartis AG
    • Bayer AG
    • Takeda Pharmaceutical Company Limited
    • Eisai Co., Ltd.
Product Code: MRR-AD36CD897E7F

The Neglected Tropical Disease Treatment Market is projected to grow by USD 10.79 billion at a CAGR of 6.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.40 billion
Estimated Year [2025] USD 6.83 billion
Forecast Year [2032] USD 10.79 billion
CAGR (%) 6.73%

A strategic framing of neglected tropical disease treatment priorities, delivery challenges, and the imperative for integrated public health interventions that drive sustained outcomes

Neglected tropical diseases remain a defining public health challenge in many low- and middle-income settings, demanding coordinated clinical, logistical, and policy responses. In recent years, the confluence of environmental change, population movements, and evolving health system capacities has reshaped how treatment interventions are prioritized and delivered. Consequently, stakeholders across public health agencies, non-governmental organizations, clinical providers, and pharmaceutical manufacturers must align their approaches to preserve treatment efficacy, extend reach, and sustain community trust.

This analysis introduces the current treatment landscape by situating core clinical interventions within broader delivery and regulatory contexts. It emphasizes the need for integrated strategies that bridge mass drug administration approaches with targeted therapies, while recognizing the role of primary care sites, community health networks, and mobile outreach in closing access gaps. To that end, the introduction sets the stage for subsequent chapters that examine systemic shifts, policy headwinds, segmentation-specific insights, and practical recommendations for leaders seeking to translate evidence into impact.

How scientific advances, shifting epidemiology, and evolving procurement models are redefining treatment paradigms and supply chain resilience for neglected tropical diseases

The treatment landscape for neglected tropical diseases is undergoing transformative shifts driven by scientific innovation, demographic pressures, and changing policy environments. Advances in diagnostic sensitivity and point-of-care testing are narrowing the gap between clinical detection and timely treatment, which in turn supports more precise use of targeted therapies alongside traditional mass drug administration campaigns. At the same time, drug development pipelines have diversified to include optimized anthelmintic regimens, combination therapies, and repurposed antibiotics that can be deployed in resource-limited settings with simplified administration protocols.

Simultaneously, broader systemic dynamics are reshaping program design. Urbanization and climate variability alter vector habitats and disease transmission patterns, prompting a recalibration of intervention zones and seasonality planning. Public procurement and supply chain resilience have become focal areas, with stakeholders investing in buffer stocks, decentralized warehousing, and digital inventory systems to reduce distribution lag. Finally, partnerships between public health authorities, non-governmental organizations, and private manufacturers are expanding, enabling collaborative financing models and pooled procurement mechanisms that enhance procurement efficiency and operational scalability.

Cumulative operational and procurement consequences stemming from United States tariff adjustments in 2025 that reshaped supply chains, sourcing strategies, and inventory planning across therapeutic categories

The introduction of tariffs and trade policy changes in 2025 materially influenced procurement dynamics and supply chain configurations for essential therapeutics used in neglected tropical disease programs. Increased tariff burdens on active pharmaceutical ingredients and formulation components amplified landed costs for some drug families, prompting procurement officers to reassess supplier portfolios and prioritize localized manufacturing where feasible. In response, supply chain managers accelerated efforts to qualify alternative suppliers, diversify logistics routes, and strengthen in-region contracting to buffer against future policy volatility.

Beyond direct cost effects, tariff-induced disruption had downstream implications for program timing and inventory planning. Organizations reliant on multi-stage international supply chains encountered longer lead times and heightened compliance requirements, which required earlier ordering windows and expanded coordination across customs, regulatory, and distribution partners. Moreover, tariff impacts intersected with existing regulatory complexity for active ingredients and finished products, intensifying the need for harmonized documentation and advance engagement with national authorities. As a consequence, program teams are increasingly embedding trade-policy scenario planning into annual procurement cycles and exploring contractual terms that allocate risk more explicitly between buyers and suppliers.

Segment-driven clinical and procurement imperatives that reconcile indication-specific needs, therapeutic classes, distribution pathways, and administration modes to optimize program delivery

A nuanced understanding of the market requires segmentation by indication, product class, delivery channel, end-user setting, route of administration, and treatment approach, each of which informs clinical decision-making and operational design. When examining disease indications such as dengue, lymphatic filariasis, onchocerciasis, schistosomiasis, and trachoma, program priorities differ markedly: vector control and rapid clinical management dominate dengue responses, whereas mass drug administration and morbidity management are central to lymphatic filariasis and onchocerciasis control efforts. Schistosomiasis interventions emphasize school- and community-based chemotherapy, and trachoma programs integrate antibiotic distribution with facial cleanliness and environmental measures.

Product-level segmentation similarly shapes procurement and clinical pathways. Anthelmintics, including widely used agents such as albendazole, ivermectin, and mebendazole, remain foundational for helminth control and require formulations suitable for mass administration. Antiarthropodals and insecticides underpin vector control strategies and are procured alongside pharmaceutical products to achieve integrated intervention packages. Antibiotics such as azithromycin and doxycycline have distinct roles in trachoma and certain bacterial sequelae, influencing dosing regimens and safety monitoring. Antiprotozoals, including meglumine, pentamidine, and suramin, cater to more specialized indications and often necessitate programmatic support for parenteral administration and adverse event surveillance.

Distribution channels also determine access dynamics. Government programs and NGO distribution platforms are primary conduits for large-scale campaigns, hospital pharmacies serve as referral hubs for complex cases, and retail pharmacies offer local access for routine care and follow-up. Correspondingly, end users vary from clinics and community health centers that deliver first-line preventive measures to hospitals and mobile camps that manage severe or rapidly evolving cases. Routes of administration-oral, parenteral, and topical-interact with service delivery capacity, with oral regimens generally preferred for scale, parenteral routes reserved for severe disease, and topical formulations supporting adjunctive care.

Finally, treatment approach differentiates program design: mass drug administration is effective for community-level burden reduction and elimination objectives, while targeted therapy allows clinicians to tailor regimens according to diagnostic confirmation and individual risk profiles. Taken together, these segmentation lenses provide a multidimensional perspective that facilitates targeted procurement, optimized clinical pathways, and tailored monitoring frameworks for diverse operational contexts.

Regional operational realities and epidemiological nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate adaptive treatment strategies and supply choices

Regional context significantly influences program priorities, regulatory navigation, and partnership models across the Americas, Europe Middle East & Africa, and Asia-Pacific, each presenting distinct epidemiological patterns and operational constraints. In the Americas, urbanization trends and heterogeneous health system capacities shape a dual focus on outbreak responsiveness for arboviral threats and sustained community-based control for helminth infections. Program implementers in this region often emphasize integration with primary healthcare platforms and leverage municipal health networks to extend outreach.

Across Europe, the Middle East & Africa, program responses contend with diverse regulatory environments and variable logistics infrastructure; integration of MDA campaigns with routine maternal and child health services has emerged as a pragmatic approach to broaden coverage in resource-limited settings. Humanitarian operations and cross-border coordination are particularly salient in parts of this region where displacement and conflict alter transmission dynamics and complicate supply continuity. In the Asia-Pacific, high population density in peri-urban zones, coupled with climatic influences on vector ecology, drives seasonally targeted interventions and school-based delivery models. Additionally, growing local manufacturing capacity and regional procurement consortia are enabling more resilient supply options, while digital health tools support community-level surveillance and adherence monitoring. These regional distinctions underline the importance of tailoring clinical protocols, distribution mechanisms, and partnership strategies to local realities.

How manufacturers, suppliers, and service providers are redefining competitive advantage through formulation innovation, localized production, and enhanced distribution capabilities

Industry participants and public-sector partners are adapting to a landscape where clinical efficacy, regulatory agility, and logistical competence determine competitive positioning. Pharmaceutical manufacturers focused on anthelmintics and antibiotics are investing in simplified dosing formulations and pediatric-friendly tablets to facilitate mass administration and improve adherence. At the same time, suppliers of antiarthropodals and insecticides are aligning formulations with integrated vector management programs, emphasizing safety profiles and environmental stewardship. Contract manufacturers and in-region production facilities are gaining strategic importance as stakeholders seek to reduce dependency on extended international supply chains and respond more nimbly to local demand fluctuations.

Service providers, including logistics firms and NGO implementers, are differentiating through expertise in cold-chain management for parenteral therapies, mobile outreach capabilities, and digital tracking systems that monitor campaign performance in real time. Regulatory consultancies and quality assurance partners play a critical role in accelerating product registration and ensuring compliance with national and regional standards. Collectively, these actors contribute to an ecosystem where collaboration, transparent contracting, and investment in capacity building are essential to sustain program momentum and expand access in challenging operational settings.

Practical strategic moves for leaders to strengthen program resilience, accelerate access, and align procurement and clinical strategies with local operational realities

Industry leaders and public health managers can advance impact by aligning strategic investments with operational realities and clinical priorities. First, prioritize formulation and delivery innovations that simplify administration and increase acceptability in community settings; this reduces reliance on intensive clinical infrastructure and supports higher coverage in mass drug administration contexts. Second, strengthen regional supplier networks and invest in local manufacturing partnerships to mitigate trade-policy risks and shorten lead times, while ensuring quality management systems are in place to maintain product integrity.

Third, integrate diagnostics and surveillance data into procurement and campaign planning so that targeted therapies complement mass administration where clinically appropriate; this will improve resource allocation and reduce unnecessary exposure to pharmacologic agents. Fourth, enhance supply chain transparency by adopting digital inventory and tracking solutions that enable proactive reallocation of stocks and more accurate anticipation of bottlenecks. Finally, deepen cross-sector collaborations that link public agencies, non-governmental implementers, clinical providers, and private manufacturers to coordinate financing, training, and community engagement. Taken together, these steps create a pragmatic roadmap for leaders to improve program resilience and accelerate progress against neglected tropical diseases.

A transparent methodology integrating clinical literature, implementation evaluations, regulatory analysis, and stakeholder interviews to ground operational conclusions in real-world evidence

The findings presented here synthesize multiple lines of evidence drawn from peer-reviewed clinical literature, program implementation reports, regulatory notices, and stakeholder interviews with procurement officers, clinicians, and supply chain specialists. Data synthesis prioritized recent peer-reviewed studies on treatment efficacy and safety, implementation evaluations of mass drug administration campaigns, and documented changes in trade and procurement policies. Qualitative inputs from field implementers and manufacturing partners informed assessments of operational feasibility and supply chain dynamics, providing real-world context to technical findings.

Analysis methods combined thematic synthesis for qualitative data with comparative review of regulatory and procurement practices across jurisdictions. Where applicable, triangulation between clinical evidence and operational experience guided conclusions about intervention suitability and distribution strategies. The methodology emphasized transparency in source selection, critical appraisal of evidence quality, and iterative validation with subject-matter experts to ensure that interpretations remain grounded in current practice and regulatory constraints.

Synthesis of strategic priorities that emphasize integration, localized capacity, and data-driven program design to sustain progress against neglected tropical diseases

In conclusion, the treatment landscape for neglected tropical diseases is at an inflection point where clinical advances, supply chain modernization, and adaptive policy responses must converge to sustain progress. Effective programs will blend mass drug administration with targeted clinical interventions, supported by stronger regional manufacturing capabilities, improved diagnostics, and digital tools that enhance supply chain responsiveness. Moreover, an emphasis on formulation innovation and community-centered delivery will be essential to expanding reach while preserving safety and acceptability.

Moving forward, stakeholders should prioritize cross-sector collaboration, investment in localized capacity, and integration of surveillance data into program design. By doing so, implementers and manufacturers can better anticipate disruptions, optimize resource use, and deliver treatments in ways that are both equitable and sustainable. These combined efforts will be critical to maintaining momentum against neglected tropical diseases in the years ahead.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of public-private partnerships for R&D acceleration in neglected tropical disease drug development
  • 5.2. Integration of smartphone-enabled rapid diagnostic testing into community control programs for schistosomiasis
  • 5.3. Adoption of mRNA vaccine platforms for novel immunization strategies against visceral leishmaniasis in endemic regions
  • 5.4. Implementation of digital supply chain management solutions to optimize last-mile distribution of neglected tropical disease treatments
  • 5.5. Surge in philanthropic and impact investment funding for combination therapies targeting cutaneous leishmaniasis
  • 5.6. Fast-track regulatory approvals for novel macrocyclic lactone formulations addressing onchocerciasis drug resistance challenges
  • 5.7. Deployment of AI-driven predictive modeling to enhance target identification in neglected tropical disease drug discovery pipelines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neglected Tropical Disease Treatment Market, by Disease Indication

  • 8.1. Dengue
  • 8.2. Lymphatic Filariasis
  • 8.3. Onchocerciasis
  • 8.4. Schistosomiasis
  • 8.5. Trachoma

9. Neglected Tropical Disease Treatment Market, by Drug Type

  • 9.1. Anthelmintics
    • 9.1.1. Albendazole
    • 9.1.2. Ivermectin
    • 9.1.3. Mebendazole
  • 9.2. Antiarthropodals
  • 9.3. Antibiotics
    • 9.3.1. Azithromycin
    • 9.3.2. Doxycycline
  • 9.4. Antiprotozoals
    • 9.4.1. Meglumine
    • 9.4.2. Pentamidine
    • 9.4.3. Suramin
  • 9.5. Insecticides

10. Neglected Tropical Disease Treatment Market, by Distribution Channel

  • 10.1. Government Programs
  • 10.2. Hospital Pharmacy
  • 10.3. NGO Distribution
  • 10.4. Retail Pharmacy

11. Neglected Tropical Disease Treatment Market, by End User

  • 11.1. Clinics
  • 11.2. Community Health Centers
  • 11.3. Hospitals
  • 11.4. Mobile Camps

12. Neglected Tropical Disease Treatment Market, by Route Of Administration

  • 12.1. Oral
  • 12.2. Parenteral
  • 12.3. Topical

13. Neglected Tropical Disease Treatment Market, by Treatment Approach

  • 13.1. Mass Drug Administration
  • 13.2. Targeted Therapy

14. Neglected Tropical Disease Treatment Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Neglected Tropical Disease Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Neglected Tropical Disease Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. GlaxoSmithKline plc
    • 17.3.2. Merck & Co., Inc.
    • 17.3.3. Merck KGaA
    • 17.3.4. Pfizer Inc.
    • 17.3.5. Sanofi S.A.
    • 17.3.6. Johnson & Johnson
    • 17.3.7. Novartis AG
    • 17.3.8. Bayer AG
    • 17.3.9. Takeda Pharmaceutical Company Limited
    • 17.3.10. Eisai Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NEGLECTED TROPICAL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. NEGLECTED TROPICAL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEGLECTED TROPICAL DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DENGUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DENGUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DENGUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DENGUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DENGUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DENGUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY LYMPHATIC FILARIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY LYMPHATIC FILARIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY LYMPHATIC FILARIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY LYMPHATIC FILARIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY LYMPHATIC FILARIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY LYMPHATIC FILARIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ONCHOCERCIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ONCHOCERCIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ONCHOCERCIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ONCHOCERCIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ONCHOCERCIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ONCHOCERCIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SCHISTOSOMIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SCHISTOSOMIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SCHISTOSOMIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SCHISTOSOMIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TRACHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TRACHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TRACHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TRACHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TRACHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TRACHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ALBENDAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ALBENDAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ALBENDAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ALBENDAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ALBENDAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ALBENDAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY IVERMECTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY IVERMECTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY IVERMECTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY IVERMECTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY IVERMECTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY IVERMECTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEBENDAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEBENDAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEBENDAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEBENDAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEBENDAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEBENDAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIARTHROPODALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIARTHROPODALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIARTHROPODALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIARTHROPODALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIARTHROPODALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIARTHROPODALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY AZITHROMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY AZITHROMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY AZITHROMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY AZITHROMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEGLUMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEGLUMINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEGLUMINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEGLUMINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEGLUMINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEGLUMINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PENTAMIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PENTAMIDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PENTAMIDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PENTAMIDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PENTAMIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PENTAMIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SURAMIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SURAMIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SURAMIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SURAMIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SURAMIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SURAMIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY INSECTICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY INSECTICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY INSECTICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY INSECTICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY INSECTICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY INSECTICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GOVERNMENT PROGRAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GOVERNMENT PROGRAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GOVERNMENT PROGRAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GOVERNMENT PROGRAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GOVERNMENT PROGRAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GOVERNMENT PROGRAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY NGO DISTRIBUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY NGO DISTRIBUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY NGO DISTRIBUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY NGO DISTRIBUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY NGO DISTRIBUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY NGO DISTRIBUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MOBILE CAMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MOBILE CAMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MOBILE CAMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MOBILE CAMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MOBILE CAMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MOBILE CAMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MASS DRUG ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MASS DRUG ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MASS DRUG ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MASS DRUG ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MASS DRUG ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MASS DRUG ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2024 (USD